Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of major depression disorder compared to venlafaxine hydrochloride sustained-release tablets, to provide evidence-based basis for clinical rational drug use.


Clinical Trial Description

The study included 80 patients with major depression disorder (aged 18 to 65 years) who meet the diagnostic criteria for depression in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Eligible patients were randomly assigned (1:1) to 8-week treatment with toludesvenlafaxine hydrochloride sustained-release tablets (n=40) or venlafaxine hydrochloride sustained-release tablets (n=40), followed up at period of enrollment as baseline and at the end of 2th, 4th and 8th weeks. Adverse events were recorded. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06278038
Study type Interventional
Source First Affiliated Hospital of Zhejiang University
Contact
Status Recruiting
Phase N/A
Start date February 22, 2024
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT02773108 - Somatic Comorbidities in Psychiatric Patients
Completed NCT02400346 - Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment Phase 3
Recruiting NCT05597566 - Predictive Effect of Neuroinflammatory Factors of the MECT in Treatment of Senile Depression
Recruiting NCT02273154 - Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Phase 4